Optimizing care of older patients with cancer in India: Comparative study of risk prediction of three assessment tools
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The SCreening for Older PErson with Cancer (SCOPE-C) tool shows better mortality prediction in Indian cancer patients compared to other screening tools. It is recommended for use in resource-limited settings.
Area Of Science
- Geriatric Oncology
- Cancer Screening Tools
- Health Outcomes Research
Background
- Geriatric assessment is crucial for older cancer patients but limited by time and expertise in routine oncology.
- Screening tools aid in identifying patients needing comprehensive assessment and predicting adverse outcomes.
- A culturally appropriate Indian tool, SCreening for Older PErson with Cancer (SCOPE-C) Version 1, was developed for patient triaging.
Purpose Of The Study
- To compare the performance of the SCOPE-C tool against frequently used screening tools like Geriatric 8 (G-8) and Vulnerable Elders Survey (VES-13).
- To evaluate the agreement and mortality risk prediction capabilities of SCOPE-C in older Indian cancer patients.
Main Methods
- A single-center study involving treatment-naïve older cancer patients (≥60 years) in North India (November 2019 - May 2022).
- Administration of SCOPE-C, G-8, and VES-13 screening tools.
- Analysis of scale agreement using Cohen's Kappa statistics and mortality risk prediction via logistic regression.
Main Results
- Moderate agreement was found between SCOPE-C and VES-13 (kappa = 0.321), with lower agreement between SCOPE-C and G-8 (kappa = 0.056).
- An unfavorable SCOPE-C score was significantly associated with higher mortality (OR: 2.07).
- VES-13 and G-8 (both cutoffs) did not show a statistically significant association with mortality.
Conclusions
- SCOPE-C Version 1 is a validated tool for the Indian population, considering literacy and socio-cultural factors.
- Despite low agreement with other scales, SCOPE-C demonstrated superior mortality risk predictive potential.
- SCOPE-C is recommended for prognostication and decision-making in resource-constrained settings like India and other LMICs.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...